Alsagaby Suliman A, Brennan Paul, Pepper Chris
Department of Medical Laboratory, College of Science, Majmaah University, Al-Zuli, Kingdom of Saudi Arabia; Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):593-606. doi: 10.1016/j.clml.2016.08.008. Epub 2016 Aug 10.
Chronic lymphocytic leukemia (CLL) is an adult neoplastic disease of B cells characterized by variable clinical outcomes. Although some patients have an aggressive form of the disease and often encounter treatment failure and short survival, others have more stable disease with long-term survival and little or no need for theraphy. In the past decade, significant advances have been made in our understanding of the molecular drivers that affect the natural pathology of CLL. The present review describes what is known about these key molecules in the context of their role in tumor pathogenicity, prognosis, and therapy.
慢性淋巴细胞白血病(CLL)是一种成人B细胞肿瘤性疾病,其临床结局各异。尽管一些患者患有侵袭性形式的该疾病,经常遭遇治疗失败和生存期短的情况,但其他患者的病情更为稳定,生存期长,很少或根本不需要治疗。在过去十年中,我们对影响CLL自然病理的分子驱动因素的理解取得了重大进展。本综述描述了这些关键分子在肿瘤致病性、预后和治疗中的作用方面的已知情况。